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BACE initiates the production of b-amyloid (Ab), the likely cause of Alzheimer’s disease (AD). In
this issue of Neuron, Tesco et al. show that during apoptosis caspase-3 cleaves the adaptor
protein GGA3, which is required for BACE lysosomal degradation, consequently stabilizing BACE
and elevating Ab generation.The b-amyloid (Ab) peptide, the likely
cause of Alzheimer’s disease (AD), is
derived from the sequential cleavage
of amyloid precursor protein (APP) by
two enzymes, the b- and g-secretases.
The b-secretase, identified as the
novel transmembrane aspartic prote-
ase b-site APP-cleaving enzyme
(BACE), initiates the production of Ab
(Vassar, 2005). Thus, BACE is a prom-
ising therapeutic target, since BACE
inhibitor drugs may reduce Ab forma-
tion and alleviate AD. Conversely, con-
ditions that increase BACE activity are
predicted to be amyloidogenic and
may exacerbate AD. Recent reports
show that levels of BACE protein and
activity are increased in AD brain (Fu-
kumoto et al., 2002; Holsinger et al.,
2002; Li et al., 2004; Yang et al.,
2003). Moreover, BACE levels rise fol-
lowing physiological stress or injury,
such as oxidative stress (Tamagno
et al., 2002), traumatic brain injury
(Blasko et al., 2004), ischemia (Wen
et al., 2004), hypoxia (Zhang et al.,
2007), and energy inhibition (Velli-
quette et al., 2005). These results imply
that age-related stress may increase
BACE levels and drive AD patho-
genesis.
In this issue of Neuron, Tesco and
colleagues (Tesco et al., 2007) report
a posttranslational mechanism of
BACE stabilization that provides in-
sight into what may give rise to the
BACE increase in AD. Interestingly,
apoptosis and caspase activation are
involved, processes that have been
linked to AD. In their previous work,
the authors showed that apoptosiselevates Ab production in cells (Tesco
et al., 2003). Moreover, this effect
was independent of caspase cleavage
of APP and therefore may have been
due to increased b-secretase activity.
These results suggested that apopto-
sis might enhance BACE processing
of APP. In the present report, Tesco
and colleagues tested this hypothesis
first by showing that apoptosis in-
creases BACE levels several fold in
neural and nonneural cells. Levels of
C99, the C-terminal APP fragment
that is the precursor of Ab, were also
elevated, caspase-3 was activated,
and all effects were blocked by the
caspase inhibitor zVAD. Interestingly,
the rise in BACE level was not the
result of increased BACE mRNA
level, suggesting a posttranscriptional
mechanism. Indeed, pulse-chase and
cycloheximide experiments showed
that apoptosis increases the protein
half-life of BACE. These results dem-
onstrate that apoptosis stabilizes
BACE, thus causing elevated b-secre-
tase activity.
Next, to determine the cause of the
BACE stabilization, the researchers
drew upon their earlier work showing
that BACE is degraded in the lyso-
some, a process that depends on a
dileucine motif in the cytosolic tail of
BACE (Koh et al., 2005). Dileucine
motifs bind Golgi-localized g-ear-
containing ARF-binding proteins
(GGAs), a family of adaptors that func-
tion in intracellular sorting (Bonifacino,
2004). Since lysosomal degradation of
the epidermal growth factor receptor
(EGFR) requires GGA3, Tesco et al.Neuron 5hypothesized that GGA3 is respon-
sible for BACE trafficking to the lyso-
some. They also reasoned that
caspase cleavage of GGA3 during
apoptosis might result in GGA3
deficiency causing the accumulation
of BACE in endosomes where Ab is
generated. Indeed, GGA3 was cleaved
into several fragments during apopto-
sis in cells and by recombinant cas-
pase-3 in cell-free assays, effects
that were blocked by zVAD. Impor-
tantly, the observed GGA3 fragment
sizes matched the predicted sizes
based on four putative caspase cleav-
age sites in the hinge domain of GGA3.
Site-directed mutagenesis of critical
aspartic acids in these sites abolished
GGA3 fragmentation during apoptosis
in cells and by recombinant caspase-3
in vitro. Intriguingly, an N-terminal
GGA3 fragment that mimics caspase
cleavage at position 313 acted like
a dominant negative (DN) and caused
BACE levels to rise in transfected cells.
These results indicate that caspase
cleavage of GGA3 may both reduce
levels of the adaptor and create a DN
molecule, thus additively stabilizing
BACE. To conclude this thorough set
of mechanistic experiments, the au-
thors used RNA interference (RNAi) to
knock down GGA3 levels in neural
and nonneural cells and showed that
GGA3 RNAi elevates levels of BACE,
C99, and Ab. The fact that DN GGA3
and GGA3 RNAi both caused BACE
elevation is strong evidence that
caspase cleavage of GGA3 under-
lies the BACE stabilization during
apoptosis.4, June 7, 2007 ª2007 Elsevier Inc. 671
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(A) Under normal conditions, BACE is transported (1) from the trans-golgi network (TGN) to the plasma membrane (PM) and undergoes endocytosis
(2a) into endosomes (E), or BACE can directly traffic to endosomes (2b). In the endosome, BACE cleaves APP (not shown) and initiates Ab formation.
GGA3 binds to the cytosolic tail of BACE and targets the enzyme (3) to the lysosome (L) for degradation. Caspase-3 is inactive under normal
conditions.
(B) During apoptosis, caspase-3 is activated and cleaves GGA3 in the hinge domain, thus reducing full-length GGA3 levels and creating a dominant-
negative molecule. As a result, BACE sorting to the lysosome is reduced, thereby stabilizing BACE in the endosome where it accumulates and ele-
vates Ab generation.To show that caspase cleavage of
GGA3 is relevant to apoptosis-
induced BACE stabilization in vivo,
Tesco et al. next used a rat model of
cerebral ischemia. Indeed, ischemia
increased BACE levels and caspase
activation. At the same time, full-length
GGA3 was reduced while caspase-
cleaved GGA3 appeared. Finally, to
show relevance to AD, the authors
demonstrated that GGA3 levels are re-
duced in AD brain and that an inverse
correlation exists between BACE and
GGA3 levels. No such correlation was
found in nondemented (ND) brain. Al-
though activated caspase-3 fragment
was not observed in AD brain, de-
creased full-length caspase-3 sug-
gested caspase activation. Interest-
ingly, GGA3 levels in AD cerebellum,
a brain region typically lacking AD pa-
thology, were not as reduced as in AD
temporal cortex. BACE levels in AD
cerebellum were similar to those in
ND, suggesting that cerebellar GGA3
levels are sufficient for BACE lyso-
somal degradation. These results im-
ply the corollary that individuals with
lower levels of GGA3, especially in
AD-susceptible brain regions, may be
at greater risk for developing AD.
The results of Tesco et al. suggest
a model of BACE stabilization in which
GGA3 normally targets BACE to the
lysosome for degradation, keeping
BACE levels and Ab generation low
(Figure 1A). However, during apopto-672 Neuron 54, June 7, 2007 ª2007 Elsesis, GGA3 is cleaved by caspase-3,
thus reducing GGA3 levels and creat-
ing DN GGA3 (Figure 1B). As a result,
BACE lysosomal degradation is re-
duced, allowing BACE to accumulate
in endosomes and drive Abproduction.
Several key questions arise from this
important study. First, characterization
of the compartment in which BACE
accumulates would help understand
both BACE trafficking and Ab forma-
tion. Further in vivo studies of the amy-
loidogenic effects of BACE stabiliza-
tion, perhaps by depleting GGA3 with
GGA3 RNAi, would be informative, es-
pecially in AD mouse models such as
APP transgenic mice. In addition, it
will be important to determine whether
caspase-3 inhibition or GGA3 overex-
pression ameliorates amyloid pathol-
ogy in APP transgenics. This work
provides a rationale for the search of
GGA3 gene mutations in AD that
reduce GGA3 function by lowering
expression, stability, or BACE binding.
Alternatively, mutations that promote
DN GGA3 formation may also be asso-
ciated with AD. Determining whether
there may be a function to BACE stabi-
lization would be of considerable inter-
est. Growing evidence suggests that
BACE is a stress-response enzyme,
although it is unclear what protective
function BACE elevation might provide
during stress, if any. Finally, other
mechanisms besides BACE stabiliza-
tion may cause BACE elevation. Forvier Inc.example, transcriptional activation of
the BACE gene occurs under hypoxia
via the transcription factor hypoxia-
inducing factor 1 (HIF1; Zhang et al.,
2007). Studies also suggest that
BACE translation may be regulated
(Lammich et al., 2004). Future investi-
gation will be required to determine
the extent to which these or other
mechanisms may contribute to the
BACE elevation in AD.
Stroke and cerebrovascular disease
are possible risk factors for AD, and
together with the results of Tesco
et al., suggest that ischemia-induced
caspase activation followed by GGA3
depletion may be a precipitating event
in AD. Alternatively, cumulative age-
related insults to the brain may
achieve similar results, thus starting
a vicious cycle of BACE elevation
and Ab generation. In conclusion, the
work of Tesco and colleagues pro-
vides critical insight into a potentially
important mechanism of BACE eleva-
tion in AD.
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systems drives the differentiation
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The molecular mechanisms responsi-
ble for the specification of distinct
sensory modalities are being intensely
investigated, not only because of the
obvious clinical importance of pain
control, but also as a powerful model
system of neuronal diversification.
Pain perception following harmful me-
chanical, thermal, and chemical stimuli
is mediated by the activation of pain-
transducing—i.e., nociceptive—sen-
sory neurons in the dorsal root ganglia
(DRG). Nociceptive, mechanoceptive,
and proprioceptive sensory neuron
subtypes emerge from migratory neu-
ral crest cells shortly after neural tube
closure and continue to diversify by
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allow them to transduce external stim-
uli into electrical activity. The genera-
tion of nociceptor cell diversity is be-
lieved to be controlled by hierarchical
interactions between cell intrinsic and
extrinsic signals (Marmigere and Ern-
fors, 2007). All nociceptive neurons ini-
tially express the transcription factor
Runx1 and the nerve growth factor
(NGF) receptor TrkA, which mediates
target-dependent cell survival during
the period of programmed cell death.
Around birth, and during the first 2 to
3 postnatal weeks, a fraction of noci-
ceptive neurons switch their neuro-
trophic factor dependence by down-
regulating expression of TrkA and
upregulating that of Ret, a signaling
subunit of the receptor complex for
members of the GDNF (glial cell line-
derived neurotrophic factor) ligand
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ipheral projections in a subclass
family. TrkA+ and Ret+ nociceptors
are also distinguished by the presence
or absence of the neuropeptides calci-
tonin gene-related peptide (CGRP)
and substance P (SP)—hence classi-
fied as peptidergic or nonpeptidergic
subtypes—and believed to mediate
inflammatory or neuropathic pain,
respectively. While developing non-
peptidergic nociceptors lose TrkA,
maintain Runx1, and gain Ret expres-
sion, peptidergic sensory neurons
retain TrkA but lose Runx1 as they
mature (Chen et al., 2006).
The contribution of NGF/TrkA sig-
naling to sensory neuron diversifica-
tion and maturation has been studied
in mice lacking the proapoptotic mole-
cule Bax, a mutation that bypasses the
early developmental requirement of
neurotrophic support for cell survival.
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